Bertina R M, van der Marel-van Nieuwkoop W, Loeliger E A
Thromb Haemost. 1979 Dec 21;42(4):1296-305.
Two spectrophotometric assays for prothrombin have been developed and compared with a one stage coagulant and an immunological assay. One of these assays (called the XAPC assay) uses a combination of factor Xa, phospholipid, Ca2+ and factor V as activator of prothrombin, and measures only normal prothrombin. The second (the ECAR assay) uses Echis carinatus venom as activator. This assay measures both normal prothrombin and PIVKA II (protein induced by vitamin K antagonists/absence). Combination of the results obtained by the XAPC and ECAR assays provides rapid and reliable information on the degree of "subcarboxylation" of prothrombin (oral anticoagulation, vitamin K deficiency). For patients on long term anticoagulant treatment the prothrombin time (Thrombotest) shows better correlation with the ratio prothrombin/prothrombin plus PIVKA II (XAPC/ECAR) than with the factor II concentration. For patients starting the anticoagulant treatment there is no correlation between the Thrombotest time and the XAPC/ECAR ratio. It seems doubtful that (a) spectrophotometric factor II assay(s) will be as useful as the prothrombin time in the control of oral anticoagulation.
已开发出两种用于凝血酶原的分光光度测定法,并与一步凝固法和免疫测定法进行了比较。其中一种测定法(称为XAPC测定法)使用因子Xa、磷脂、Ca2+和因子V的组合作为凝血酶原的激活剂,并且仅测量正常凝血酶原。第二种(ECAR测定法)使用锯鳞蝰蛇毒作为激活剂。该测定法可测量正常凝血酶原和PIVKA II(维生素K拮抗剂/缺乏诱导的蛋白质)。通过XAPC和ECAR测定法获得的结果相结合,可提供有关凝血酶原“亚羧化”程度(口服抗凝、维生素K缺乏)的快速可靠信息。对于长期接受抗凝治疗的患者,凝血酶原时间(血栓试验)与凝血酶原/凝血酶加PIVKA II的比率(XAPC/ECAR)的相关性比与因子II浓度的相关性更好。对于开始抗凝治疗的患者,血栓试验时间与XAPC/ECAR比率之间没有相关性。分光光度法测定因子II在口服抗凝控制中是否会像凝血酶原时间一样有用,这似乎值得怀疑。